ImmunoGen rescues its product

ImmunoGen rescues its product ImmunoGen Inc. (IMGN), which has dropped Roussel-Uclaf as its European development and marketing partner for Oncolysin B, hopes to conclude a new partnership within nine to 18 months.

The company's lead product, mired in an unfinished Phase I European trial since 1991, is a year behind IMGN's U.S. product timetable, according to spokesperson Mark Ratner. However, Ratner

Read the full 654 word article

How to gain access

Continue reading with a
two-week free trial.